A statement released earlier today by Liberum Capital about AstraZeneca PLC (LON:AZN) maintains the target price at 5,200.00GBX
- Updated: October 3, 2016
Liberum Capital hold steady the target of AstraZeneca PLC (LON:AZN) at 5,200.00GBX stating a potential upside of 0.04%.
On 10/3/2016, JP Morgan Cazenove released a statement for AstraZeneca PLC (LON:AZN) maintained the target price at 4,900.00GBX that suggested a downside of -0.02%.
Boasting a price of 5,006.00GBX, AstraZeneca PLC (LON:AZN) traded -0.96% lower on the day. With the last stock price close up 13.08% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. AstraZeneca PLC has recorded a 50-day average of 5,007.50GBX and a two hundred day average of 4,415.10GBX. Volume of trade was down over the average, with 383,283 shares of AZN changing hands under the typical 2,562,370
With a total market value of 0 GBX, AstraZeneca PLC has price-earnings ratio of 28.53 with a one year low of 3,680.00GBX and a one year high of 5,505.00GBX .
A total of 29 equity analysts have released a ratings update on AZN. Four equity analysts rating the company a strong buy, fourteen equity analysts rating the company a buy, thirteen equity analysts rating the company a hold, two equity analysts rating the company a underperform, and finally one equity analyst rating the company a sell with a one year target of 61.96GBX.
Brief Synopsis About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.